Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.38 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.38 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29892832 | 0.85 | PDE10A (0.47) | MAPK8NR1H4CDK9SMN1; SMN2CDK1 | |
| SCHEMBL31343882 | 0.65 | BACE1 (0.65) | SMN1; SMN2 | |
| SCHEMBL9051857 | 0.64 | GRM2 (0.41) | SMN1; SMN2 | |
| SCHEMBL2866010 | 0.63 | CSNK1E (0.39) | SMN1; SMN2CSNK1E | |
| SCHEMBL2868815 | 0.63 | CSNK1E (0.32) | CSNK1E | |
| SCHEMBL2870860 | 0.63 | CSNK1E (0.32) | CSNK1E | |
| SCHEMBL2785512 | 0.63 | ALDH1A1 (0.50) | SMN1; SMN2 | |
| SCHEMBL8239615 | 0.62 | ADORA3 (0.56) | MAPK8CDK1FLT3 | |
| SCHEMBL12575075 | 0.62 | ADORA3 (0.55) | MAPK8 | |
| SCHEMBL26605849 | 0.62 | MAPK8 (0.54) | MAPK8SMN1; SMN2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220342-A1 | Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome | BAKTHAVATCHALAM RAJAGOPAL (US) | 2003-11-27 | — | — | US | disclosed |
| US-6589952-B2 | Imidazo(1,2-a)pyrazines containing an aryl or heteroaryl group are useful as (corticotropin releasiang factor) CRF receptor antagonists in the treatment of various neurological and psychological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-08 | — | — | US | disclosed |
| EP-1301511-A2 | IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020049208-A1 | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-25 | — | — | US | disclosed |
| WO-2002006286-A2 | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220342-A1 | Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome | SCN5A, HRH2, CHRNA5 | MAPK8 3415/4885PLAU 4753/4885NR1H4 26/4885 |
| US-20020049208-A1 | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders | CRHR1, CRHR2, CRH | MAPK8 3211/4885PLAU 2780/4885NR1H4 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.